[Featured Stock] The Future Without Fentanyl Depends on Vibozon... Trump Pushes to Eliminate 'Zombie Drugs'

Biosolution Pharmaceutical is showing strong performance. The non-narcotic analgesic 'Onapraju' (generic name Opiranserin) has obtained product approval from the Korea Ministry of Food and Drug Safety, raising expectations for rapid growth this year. Since it received product approval domestically, there is also growing anticipation for active discussions on exports and technology transfers.

As the inauguration of Donald Trump, the President-elect of the United States, approaches, the issue of fentanyl, known as the 'zombie drug,' is gaining renewed attention. Concerns are emerging that fentanyl could become another flashpoint in the dispute between the U.S. and China. Given the high demand for non-narcotic analgesic injectables in the global market, Biosolution Pharmaceutical's sales are expected to increase rapidly once it enters overseas markets.

At 3:03 PM on the 20th, Biosolution Pharmaceutical was trading at 7,550 KRW, up 11.19% from the previous trading day.

The damage caused by fentanyl in the United States is severe. According to an analysis released by the U.S. Centers for Disease Control and Prevention (CDC) in March last year, among approximately 110,000 drug overdose deaths in the U.S. in 2023, 75,000 were due to fentanyl and other opioid analgesics. A report published in April last year by the U.S. House of Representatives' U.S.-China Strategic Competition Special Committee stated that fentanyl caused damages amounting to 1.5 trillion dollars in 2020 alone.

The second Trump administration is highly likely to use the fentanyl issue not as a health problem but as a means of economic and trade pressure. On November 25 last year, Trump posted on his social media platform Truth Social that if the problem of drug imports such as fentanyl is not resolved, he would impose additional tariffs on China immediately after his inauguration on January 20 next year. The U.S. and China are expected to enter a 'trade war,' and the fentanyl issue is anticipated to be one of the key issues heightening tensions in the trade war.

Biosolution Pharmaceutical expects that the approval of Onapraju will bring revolutionary changes to the market for moderate or higher pain treatments with high unmet medical needs, as there are no alternatives other than narcotic analgesics. From the clinical stage, Onapraju has been evaluated as a 'game changer' in the medical community for showing rapid pain relief effects with fewer side effects and no addiction risk compared to narcotic analgesics.

Lee Doohyun, Chairman of the Biosolution Group, recently stated in an interview with the media, "2025 will be the inaugural year for Biosolution Pharmaceutical to emerge as a mid-sized pharmaceutical company selling new drugs."

Chairman Lee explained, "It is effective against substance abuse such as drug addiction, and we are currently collaborating with addiction experts in the U.S. to apply for research funding from the U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH)." He added, "We received very good scores in the first evaluation."

According to the Korea Health Industry Development Institute, the global non-narcotic analgesic market is expected to reach approximately 100 trillion KRW by 2030. Biosolution Pharmaceutical is also developing an oral non-narcotic analgesic as a follow-up to Onapraju.